Hanson Wade Group have taken the decision to cancel this meeting. Please do accept our apologies for any inconvenience or disappointment this will cause. Please register your interest here if you would like updates on the meeting or topic
Continue the conversation at the next event in series!
October 22-23, 2025
Boston, MA
Free to Attend for Drug Developers, Academics, & Researchers
Welcome to the Inaugural Multi-Omics Based Drug Discovery & Development
The Industry-Led Forum Dedicated to Expanding the Applications of Multi-Omics Across Therapeutic Development
With advances in computing infrastructure and omics technologies within the market, biopharma leaders are increasingly adopting multi-omics within their workflows to accelerate drug discovery and development. In parallel, technology providers are expanding their multi-omics toolkits, with Illumina announcing a new suite of technologies and Element Biosciences raising $277M to develop differentiated products.
The Inaugural Multi-Omics Based Drug Discovery & Development Summit was been positioned as the premier event for industry leaders to successfully integrate genomics, epigenomics, transcriptomics, proteomics and metabolomics data and apply omics insights to advance therapeutic development across the pipeline.
60+ leaders in Computational Biology, Biomarker Discovery, Translational Research, and Pathology were set to unite to uncover case studies on the use of harmonized omics data to de-risk clinical trials, inform patient stratification, identify novel targets and generate a holistic understanding of health and pathology.
Staying at the forefront of innovation is essential. This meeting provides access to new technologies, analytical methods, and therapeutic modalities that are shaping the future of personalized medicine and precision health
Sonoma Biotherapeutics
From Data Collection to Clinical Applications
Hear From Our Speakers
'These conversations are essential for driving
standardization, building consensus on best practices,
and improving data reproducibility across the community.
Such collaboration accelerates the development of robust,
translatable workflows in multi-omics research'
Senior Scientist
‘As an academic scientist, it’s not always possible to meet and interact with folks in pharma and biotechnology industries. The ability to bridge connections between academia and industry would be fantastic to enable future discoveries’
Assistant Professor
Explore Related Events
